https://www.selleckchem.com/products/protac-tubulin-degrader-1.html 0004) were higher in failure cases than in cured cases. Multivariate logistic regression analysis indicated significant associations between the treatment failure with tympanic membrane scores and acute rhinosinusitis scores on day 5, and the antimicrobial treatment regimen. Improvement of acute rhinosinusitis and tympanic membrane scores on day five were important predictive features in failure of treatment for pediatric AOM. These results will be useful when discussing the treatment decisions with the patient's parents. Improvement of acute rhinosinusitis and tympanic membrane scores on day five were important predictive features in failure of treatment for pediatric AOM. These results will be useful when discussing the treatment decisions with the patient's parents. Arbekacin is the first aminoglycoside antibacterial agent approved for treating methicillin-resistant Staphylococcus aureus infection in Japan. Although therapeutic drug monitoring (TDM) is recommended during arbekacin treatment, little evidence for the target exposure and once-daily dosing has been reported. This study aimed to clarify the target peak/trough concentrations and the effectiveness of once-daily dosing of arbekacin against nephrotoxicity or treatment failure via meta-analysis. A literature search was performed using MEDLINE, Cochrane Library, and Ichushi-Web. Nine observational cohort studies met the inclusion criteria. A peak arbekacin concentration of ≥15-16μg/mL did not exhibit a statistically significant lower risk of treatment failure (risk ratio [RR]=0.61, 95% confidence interval [CI]=0.30-1.24). A trough arbekacin concentration of <2μg/mL resulted in a significantly lower risk of nephrotoxicity (RR=0.30, 95% CI=0.15-0.61). Once-daily dosing significantly reduced the risk of treatment failure (RR=0.61, 95% CI=0.39-0.97) but not nephrotoxicity (RR=0.54, 95% CI=0.16-1.75). Once-daily dosing can improve the therapeuti